The inhibitory potential of Fc receptor homolog 4 on memory B cells
Rattachement africain : us, ca. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Fc receptor homolog 4 (FcRH4) is a B cell-specific member of the recently identified family of FcRHs whose intracellular domain contains three potential immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The signaling potential of this receptor, shown here to be preferentially expressed by memory B cells, was compared with the inhibitory receptor FcgammaRIIb in B cells expressing either WT FcgammaRIIb or chimeric proteins in which the intracellular domain of FcRH4 was fused to the transmembrane and extracellular domains of FcgammaRIIb. Coligation of the FcgammaRIIb/FcRH4 chimeric protein with the B cell receptor (BCR) led to tyrosine phosphorylation of the two membrane-distal tyrosines and profound inhibition of BCR-mediated calcium mobilization, whole cell tyrosine phosphorylation, and mitogen-activated protein (MAP)-kinase activation. Mutational analysis of the FcRH4 cytoplasmic region indicated that the two membrane-distal ITIMs are essential for this inhibitory potential. Phosphopeptides corresponding to these ITIMs could bind the Src homology 2 (SH2) domain-containing tyrosine phosphatases SHP-1 and SHP-2, which associated with the WT FcRH4 and with mutants having inhibitory capability. These findings indicate the potential for FcRH4 to abort B cell receptor signaling by recruiting SHP-1 and SHP-2 to its two membrane distal ITIMs.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The inhibitory potential of Fc receptor homolog 4 on memory B cells
- Date Crossref
- 03/11/2003
- Éditeur
- National Academy of Sciences
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Howard Hughes Medical Institute pays non établi dans la noticeStructure de recherche
-
University of British Columbia pays non établi dans la noticeUniversité ou école supérieure
-
University of Alabama at Birmingham Divisions of Developmental and Clinical Immunology and Hematology/Oncology pays non établi dans la noticeUniversité ou école supérieure
Howard Hughes Medical Institute, University of British Columbia et Divisions of Developmental and Clinical Immunology and Hematology/Oncology — University of Alabama at Birmingham.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.